Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 142

Sort by

Sort Order Select

Journal Articles

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Blood (2023) 142 (Supplement 1): 1831.

https://doi.org/10.1182/blood-2023-180561

Published: 2023

Journal Articles

Development and Efficacy of a Novel Bromodomain and Extraterminal Domain Degrader K-256 in MYC/BCL2-Related Lymphoma

Kastuya Furukawa, Kazuyuki Shimada, Masahiro Esaki, Kentaro Tanaka, Keisuke Yamamoto, Kiyotoshi Mori, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 5008.

https://doi.org/10.1182/blood-2023-179334

Published: 2023

Journal Articles

Suppression of Super-Enhancer-Driven TAL1 Expression By KLF4 in T-Cell Acute Lymphoblastic Leukemia

Mina Noura, Takahiko Yasuda, Shinobu Tsuzuki, Hidemasa Matsuo, Hitoshi Kiyoi, Fumihiko Hayakawa

Blood (2023) 142 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2023-173640

Published: 2023

Journal Articles

Analysis of Metabolic Mechanism of CD19CAR-T with CD79A/CD40 Co-Stimulatory Domain Based on Comparison with Established CAR-Ts

Yuki Takeuchi, Seitaro Terakura, Shiho Hirano, Hirofumi Yokota, Shihomi Kuwano, Masahide Osaki, Yoshitaka Adachi, Kanae Imai, Jakrawadee Julamanee, Ryo Hanajiri, Makoto Murata, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 2057.

https://doi.org/10.1182/blood-2023-179842

Published: 2023

Journal Articles

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Yoshihiro Hatta, Fumihiko Hayakawa, Etsuko Yamazaki, Tohru Murayama, Takeshi Saito, Satoru Takada, Nobuaki Dobashi, Shuichi Ota, Yasuhisa Yokoyama, Masatsugu Tanaka, Shinya Sato, Shigeki Ohtake, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Itaru Matsumura, Yasushi Miyazaki, Hitoshi Kiyoi

Blood (2023) 142 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2023-178332

Published: 2023

Journal Articles

Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study

Blood (2022) 140 (Supplement 1): 6030–6032.

https://doi.org/10.1182/blood-2022-165864

Published: 2022

Journal Articles

iPSC-Derived HLA-A2 CAR Tregs Showed Suppression of GvHD in a Xenograft Model

Hisashi Yano, Takayuki Sato, Tokuyuki Shinohara, Keiko Koga, Shoichi Iriguchi, Atsushi Matsuda, Yasuyuki Miyake, Yoshiaki Kassai, Hitoshi Kiyoi, Shin Kaneko

Blood (2022) 140 (Supplement 1): 2365–2366.

https://doi.org/10.1182/blood-2022-156904

Published: 2022

Journal Articles

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Blood (2022) 140 (Supplement 1): 124–126.

https://doi.org/10.1182/blood-2022-156613

Published: 2022

Journal Articles

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

Blood (2022) 139 (12): 1850–1862.

https://doi.org/10.1182/blood.2021011921

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group

Blood (2021) 138 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2021-149110

Published: 2021

Journal Articles

Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT

Blood (2021) 138 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2021-147587

Published: 2021

Journal Articles

Nilotinib and Dasatinib Evoked Distinct Immune Effects during Tfr Phase of Each Discontinuation Trial

Yuki Fujioka, Naoto Takahashi, Shigeki Ohtake, Yoshiko Atsuta, Yosuke Minami, Noriyoshi Iriyama, Hitoshi Kiyoi, Yasushi Miyazaki, Itaru Matsumura

Blood (2021) 138 (Supplement 1): 3580.

https://doi.org/10.1182/blood-2021-147312

Published: 2021

Journal Articles

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Blood (2021) 137 (11): 1491–1502.

https://doi.org/10.1182/blood.2020007245

Published: 2021

Includes: Supplemental data

Journal Articles

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134168

Published: 2020

Journal Articles

Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells

Tatsunori Goto, MD, Makoto Murata, MD PhD, Tetsuya Nishida, MD PhD, Seitaro Terakura, MD PhD, Sonoko Kamoshita, MD, Yuichi Ishikawa, MD PhD, Yoko Ushijima, MD PhD, Yoshiya Adachi, MD PhD, Katsuyoshi Kato, PhD, Akihiro Hirakawa, PhD, Satoshi Nishiwaki, MD PhD, Nobuhiro Nishio, MD PhD, Yoshiyuki Takahashi, MD PhD, Yoshihisa Kodera, MD, Tadashi Matsushita, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2004.

https://doi.org/10.1182/blood-2019-122101

Published: 2019

Journal Articles

Guided Polarization of iPSC-Derived CD4SP Helper T Cells By CRISPR/Cas9-Based Genome-Editing

Hisashi Yano, MD, Tokuyuki Shinohara, PhD, Keiko Koga, PhD, Shoichi Iriguchi, PhD, Yasuyuki Miyake, Xuewei Song, Megumi Tada, Yoshiaki Kassai, PhD, Hitoshi Kiyoi, MD PhD, Shin Kaneko, MD PhD

Blood (2019) 134 (Supplement_1): 1937.

https://doi.org/10.1182/blood-2019-122193

Published: 2019

Journal Articles

Staurosporine Induces Caspase-Dependent Proteolysis of MEF2D-Fusion Protein and Cell Death Selective to MEF2D-Fusion-Positive ALL Cells

Naoyuki Tange, MD, Fumihiko Hayakawa, MD, PhD, Takahiko Yasuda, MD, PhD, Hideyuki Yamamoto, MD, Daiki Hirano, MD, PhD, Shinobu Tsuzuki, MD,PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 1349.

https://doi.org/10.1182/blood-2019-123602

Published: 2019

Journal Articles

Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3 -ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study

Blood (2019) 134 (Supplement_1): 1328.

https://doi.org/10.1182/blood-2019-124394

Published: 2019

Journal Articles

Development of Predictive Biomarker and Optimal Treatment Strategy with FLT3 Inhibitors in Acute Myeloid Leukemia

Jeong Hui Kim, Yasuhiko Harada, MD PhD, Yuichi Ishikawa, MD PhD, Naomi Kawashima, MD PhD, Marie Nakashima, MD, Yoko Ushijima, MD PhD, Takahiro Nishiyama, MD PhD, Tatsunori Goto, MD PhD, Nobuaki Fukushima, MD PhD, Rika Kihara, MD PhD, Tomohiro Kajiguchi, MD PhD, Koichi Watamoto, MD PhD, Akio Kohno, MD PhD, Kunio Kitamura, MD PhD, Yukiyasu Ozawa, MD PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 1418.

https://doi.org/10.1182/blood-2019-127610

Published: 2019

Journal Articles

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

Satoshi Kitazawa, PhD, Yukiko Ishii, PhD, Keiko Makita-Suzuki, Koichi Saito, PhD, Kensuke Takayanagi, Hiromi Sugihara, Shun Matsuda, PhD, Takayuki Yamakawa, PhD, Yasuhiro Tsutsui, Tadashi Tanaka, Tomohisa Hatta, PhD, Tohru Natsume, PhD, Toru Kondo, PhD, Yuichi Ishikawa, MD PhD, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2663.

https://doi.org/10.1182/blood-2019-121869

Published: 2019

NARROW

Thrombotic and Bleeding Events in Japanese Adolescent and Young Adult PV and ET: Results from Japanese Multicenter Retrospective Study

Development and Efficacy of a Novel Bromodomain and Extraterminal Domain Degrader K-256 in MYC/BCL2-Related Lymphoma

Suppression of Super-Enhancer-Driven TAL1 Expression By KLF4 in T-Cell Acute Lymphoblastic Leukemia

Analysis of Metabolic Mechanism of CD19CAR-T with CD79A/CD40 Co-Stimulatory Domain Based on Comparison with Established CAR-Ts

Real-World Data in a Prospective Clinical Observation Study for Newly Diagnosed Adult Acute Lymphoblastic Leukemia, the JALSG ALL-CS-12 : Advanced Age Is a Poor Prognostic Factor

Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study

iPSC-Derived HLA-A2 CAR Tregs Showed Suppression of GvHD in a Xenograft Model

Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations

Impact of Nelarabine, Intensive L-Asparaginase, and Protracted Intrathecal Therapy on Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group and the Japan Adult Leukemia Study Group

Outcomes of Transplant-Eligible Patients with Myelodysplastic Syndrome-Refractory Anemia with Excess Blasts Registered in a Prospective Observational Study: The JALSG-CS11-MDS-SCT

Nilotinib and Dasatinib Evoked Distinct Immune Effects during Tfr Phase of Each Discontinuation Trial

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells

Guided Polarization of iPSC-Derived CD4SP Helper T Cells By CRISPR/Cas9-Based Genome-Editing

Staurosporine Induces Caspase-Dependent Proteolysis of MEF2D-Fusion Protein and Cell Death Selective to MEF2D-Fusion-Positive ALL Cells

Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3 -ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study

Development of Predictive Biomarker and Optimal Treatment Strategy with FLT3 Inhibitors in Acute Myeloid Leukemia

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only